Probiotics in COPD: Effects on Symptoms, Lung Function, and Inflammation

Korábbi kezelés

• patients on long-term systemic corticosteroid and immunosuppressive therapy (oral or intravenous form) as well as antifungal therapy,
• patients who have recently participated in other clinical trials or have received experimental therapy,
• patients with active alcoholism or drug addiction,
• patients who have recently undergone surgery,
• patients who have taken any probiotic preparations within one month before the start of the study,

Más betegség

• patients diagnosed with serious comorbidities such as severe cardiovascular diseases (severe heart failure, acute coronary syndrome, or percutaneous coronary intervention within 6 months, uncontrolled tachy/bradyarrhythmias), patients with severe renal failure and a placed central venous catheter, patients with severe liver damage (Child-Pugh class C), patients with infectious hepatitis or HIV, active bloody diarrhea;
• patients who have had a stroke within the past 3 months;
• patients who have had a COPD exacerbation within the past two months and are not in a stable condition,
• patients with a history of lung surgery or serious respiratory diseases other than COPD (active tuberculosis, sarcoidosis, pulmonary fibrosis, severe bronchiectasis, pulmonary aspergillosis, etc.),
• patients with a history of severe allergic reactions or hypersensitivity to the components of the probiotic preparation,
• patients with severe psychiatric diagnoses or those with significant physical or cognitive limitations that would interfere with following the study protocol,

Egyéb

• patients undergoing active oncological and hematological treatment;
• transplanted patients, including allograft recipients;
• patients diagnosed with asthma,
• pregnant or breastfeeding women,
• patients whose COPD treatment is changed during the course of the study.

• Patients with a previously established diagnosis of COPD, regardless of the degree of airflow obstruction on pulmonary function testing.
• Age over 18 years, regardless of sex.
• Stable disease without exacerbations during the past two months (8 weeks).
• Stable disease without changes to maintenance therapy during the past two months (8 weeks).
• Patients with an mMRC score of 1 or higher.
• Signed informed consent.